Tag: EGFR-mutant NSCLC treatment

Home / EGFR-mutant NSCLC treatment

Categories

Osimertinib with chemotherapy is approved by the USFDA for EGFR-mutated non-small cell lung cancer

The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-s...
egfr-mutant-nsclc-treatment

Scan the code